The 3Mg trial: A randomised controlled trial of intravenous or nebulised magnesium sulphate versus placebo in adults with acute severe asthma

Health Technology Assessment

Volumn 18, Issue 22, 2014, Pages 1-167

  Goodacre, Steve ^a   Cohen, Judith ^a   Bradburn, Mike ^a   Stevens, John ^a   Gray, Alasdair ^b   Benger, Jonathan ^c   Coats, Tim ^d  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^d LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

IPRATROPIUM BROMIDE; MAGNESIUM SULFATE; PLACEBO; PREDNISOLONE; SALBUTAMOL; BRONCHODILATING AGENT;

ABSENTEEISM; ADULT; ARTICLE; ASSISTED VENTILATION; ASTHMA; BLOOD PRESSURE; BREATHING RATE; CAUSE OF DEATH; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CONTRAINDICATION; DYSPNEA; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH SERVICE; HEART ARREST; HEART ARRHYTHMIA; HEART RATE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NASOTRACHEAL INTUBATION; NEBULIZER; OXYGEN SATURATION; OXYGEN THERAPY; PATIENT SATISFACTION; PEAK EXPIRATORY FLOW; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UNITED KINGDOM; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; ACUTE DISEASE; ADOLESCENT; AGE DISTRIBUTION; AGED; CLINICAL TRIAL; COMPLICATION; EMERGENCY HEALTH SERVICE; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SEX RATIO; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ACUTE DISEASE; ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ASTHMA; BRONCHODILATOR AGENTS; DOUBLE-BLIND METHOD; DYSPNEA; EMERGENCY SERVICE, HOSPITAL; FEMALE; GREAT BRITAIN; HUMANS; INFUSIONS, INTRAVENOUS; MAGNESIUM SULFATE; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT ADMISSION; PATIENT SATISFACTION; QUALITY-ADJUSTED LIFE YEARS; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; VISUAL ANALOG SCALE; YOUNG ADULT;

EID: 84900310814     PISSN: 13665278     EISSN: 20464924     Source Type: Journal    
DOI: 10.3310/hta18220     Document Type: Article

References (70)

1. The NHS Health and Social Care Information Centre. Hospital Episodes Statistics for England, 1998-2012. URL: www. hesonline. nhs. uk/(accessed 6 December 2012).
2. British Thoracic Society/Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma: A National Clinical Guideline. 2012. URL: www. britthoracic. org. uk/Portals/0/Guidelines/AsthmaGuidelines/sign101%20Jan%202012. pdf (accessed 20 January 2014).
3. The Magpie Trial Collaborative Group. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877-90.
4. Tzivoni D, Banai S, Schuger C, Benhorin J, Keren A, Gottlieb S, et al. Treatment of torsade de pointes with magnesium sulfate. Circulation 1988; 77: 392-7. http://dx. doi. org/10. 1161/01. CIR. 77. 2. 392.
5. British Medical Association and the Royal Pharmaceutical Society of Great Britain. British National Formulary. 64th edition. London: BMJ Publishing Group; 2012.
6. Farouque HM, Sanders P, Young GD. Intravenous magnesium sulfate for acute termination of sustained monomorphic ventricular tachycardia associated with coronary artery disease. Am J Cardiol 2000; 86: 1270-2. http://dx. doi. org/10. 1016/S0002-9149(00)01219-4.
7. Thel MC, Armstrong AL, McNulty SE, Califf RM, O'Connor CM. Randomised trial of magnesium in in-hospital cardiac arrest. Duke Internal Medicine Housestaff. Lancet 1997; 350: 1272-6.
8. Woods KL, Fletcher S. Long-term outcome after intravenous magnesium sulphate in suspected acute myocardial infarction: the second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). Lancet 1994; 343: 816-19. http://dx. doi. org/10. 1016/S0140-6736(94)92024-9.
9. Ho KM, Sheridan DJ, Paterson T. Use of intravenous magnesium to treat acute onset atrial fibrillation: a meta-analysis. Heart 2007; 93: 1433-40. http://dx. doi. org/10. 1136/hrt. 2006. 111492.
10. Onalan O, Crystal E, Daoulah A, Lau C, Crystal A, Lashevsky I. Meta-analysis of magnesium therapy for acute management of rapid atrial fibrillation. Am J Cardiol 2007; 99: 1726-32. http://dx. doi. org/10. 1016/j. amjcard. 2007. 01. 057.
11. Mohammed S, Goodacre S. Intravenous and nebulised magnesium sulphate for acute asthma: systematic review and meta-analysis. Emerg Med J 2007; 24: 823-30. http://dx. doi. org/10. 1136/emj. 2007. 052050.
12. Rowe BH, Bretzlaff JA, Bourdon C, Bota GW, Camargo CA. Intravenous magnesium sulphate treatment for acute asthma in the emergency department: a systematic review of the literature. Ann Emerg Med 2000; 36: 181-90.
13. Alter HJ, Koepsell TD, Hilty WM. Intravenous magnesium as an adjuvant in acute bronchospasm: a meta-analysis. Ann Emerg Med 2000; 36: 191-7. http://dx. doi. org/10. 1067/mem. 2000. 109170.
14. Rodrigo G, Rodrigo C, Burschtin O. Efficacy of magnesium sulfate in acute adult asthma: a meta-analysis of randomized trials. Am J Emerg Med 2000; 18: 216-21. http://dx. doi. org/10. 1016/S0735-6757(00)90024-X.
15. Cheuk DKL, Chau TCH, Lee SL. A meta-analysis on intravenous magnesium sulphate for treating acute asthma. Arch Dis Child 2005; 90: 74-7. http://dx. doi. org/10. 1136/adc. 2004. 050005.
16. Skobeloff EM, Spivey WH, McNamara RM, et al. Intravenous magnesium sulphate for the treatment of acute asthma in the emergency department. JAMA 1989; 262: 1210-13.
17. Green SM, Rothrock SG. Intravenous magnesium for acute asthma: failure to decrease emergency treatment duration or need for hospitalization. Ann Emerg Med 1992; 21: 260-5. http://dx. doi. org/10. 1016/S0196-0644(05)80885-6.
18. Tiffany BR, Berk WA, Todd IK, White SR. Magnesium bolus or infusion fails to improve expiratory flow in acute asthma exacerbations. Chest 1993; 104: 831-4. http://dx. doi. org/10. 1378/chest. 104. 3. 831.
19. Matusiewicz SP, Cusack S, Greening AP, Crompton GK. A double blind placebo controlled parallel group study of intravenous magnesium sulphate in acute severe asthma. Eur Res 1994; 7: 14S.
20. Skorodin MS, Tenholder MF, Yetter B, Owen KA, Waller RF, Khandelwahl S, et al. Magnesium sulfate in exacerbations of chronic obstructive pulmonary disease. Arch Intern Med 1995; 155: 496-500. http://dx. doi. org/10. 1001/archinte. 155. 5. 496.
21. Bloch H, Silverman R, Mancherje N, Grant S, Jagminas L, Scharf SM. Intravenous magnesium sulfate as an adjunct in the treatment of acute asthma. Chest 1995; 107: 1576-81. http://dx. doi. org/10. 1378/chest. 107. 6. 1576.
22. Silverman R, Osborn H, Runge J, Gallagher EJ, Chiang W, Feldman J, et al. IV magnesium sulfate in the treatment of acute severe asthma. A multicentre randomized controlled trial. Chest 2002; 122: 489-97. http://dx. doi. org/10. 1378/chest. 122. 2. 489.
23. Boonyavorakul C, Thakkinstan A, Charonepan P. Intravenous magnesium sulfate in acute severe asthma. Respirology 2000; 5: 221-5. http://dx. doi. org/10. 1046/j. 1440-1843. 2000. 00252. x.
24. Porter RS, Nester BA, Braitman LE, Geary U, Dalsey WC. Intravenous magnesium is ineffective in adult asthma, a randomized trial. Eur J Emerg Med 2001; 8: 9-15. http://dx. doi. org/10. 1097/00063110-200103000-00003.
25. Ciarallo L, Sauer AH, Shannon MW. Intravenous magnesium therapy for moderate to severe pediatric asthma: Results of a randomized, placebo-controlled trial. J Pediatr 1996; 129: 809-14. http://dx. doi. org/10. 1016/S0022-3476(96)70023-9.
26. Devi PR, Kumar L, Singhi SC, Prasad R, Singh M. Intravenous magnesium sulfate in acute severe asthma not responding to conventional therapy. Indian Pediatr 1997; 34: 389-97.
27. Gurkan F, Haspolat K, Bosnak M, Dikici B, Derman O, Ece A. Intravenous magnesium sulphate in the management of moderate to severe acute asthmatic children nonresponding to conventional therapy. Eur J Emerg Med 1999; 6: 201-5. http://dx. doi. org/10. 1097/00063110-199909000-00005.
28. Scarfone RJ, Loiselle JM, Joffe MD, Mull CC, Stiller S, Thompson K, et al. A randomized trial of magnesium in the emergency department treatment of children with asthma. Ann Emerg Med 2000; 36: 572-8. http://dx. doi. org/10. 1067/mem. 2000. 111060.
29. Ciarallo L, Brousseau D, Reinert S. Higher-dose intravenous magnesium therapy for children with moderate to severe acute asthma. Arch Pediatr Adolesc Med 2000; 154: 979-83. http://dx. doi. org/10. 1001/archpedi. 154. 10. 979.
30. Santana JC, Barreto SS, Piva JP, Garcia PC. Randomized clinical trial of intravenous magnesium sulfate versus salbutamol in early management of severe acute asthma in children. J Pediatr 2001; 77: 279-87.
31. Singh AK, Gaur S, Kumar R. A randomised controlled trial of intravenous magnesium sulphate as an adjunct to standard therapy in acute severe asthma. Iran J Allergy Asthma Immunol 2008; 7: 221-9.
32. Blitz M, Blitz S, Hughes R, Diner B, Beasley R, Knopp J, et al. Aerosolized magnesium sulfate in acute asthma: A systematic review. Chest 2005; 128: 337-44.
33. Villeneuve EJ, Zed PJ. Nebulized Magnesium Sulfate in the Management of Acute Exacerbations of Asthma. Ann Pharmacother 2006; 40: 1118-24. http://dx. doi. org/10. 1345/aph. 1G496.
34. Nannini LJ, Pendino JC, Corna RA, Mannarino S, Quispe R. Magnesium sulfate as a vehicle for nebulized salbutamol in acute asthma. Am J Med 2000; 108: 193-7. http://dx. doi. org/10. 1016/S0002-9343(99)00463-5.
35. Bessmertny O, DiGregorio RV, Cohen H, Becker E, Looney D, Golden J, et al. A randomized clinical trial of nebulized magnesium sulfate in addition to albuterol in the treatment of acute mild-to-moderate asthma exacerbations in adults. Ann Emerg Med 2002; 39: 585-91. http://dx. doi. org/10. 1067/mem. 2002. 123300.
36. Hughes R, Goldkorn A, Masoli M, Weatherall M, Burgess C, Beasley R. Use of isotonic nebulised magnesium sulphate as an adjuvant to salbutamol in treatment of severe asthma in adults: randomised placebo-controlled trial. Lancet 2003; 361: 2114-17. http://dx. doi. org/10. 1016/S0140-6736(03)13721-X.
37. Kokturk N, Turktas H, Kara P, Mullaoglu S, Yilmaz F, Karamercan A. A randomized clinical trial of magnesium sulphate as a vehicle for nebulized salbutamol in the treatment of moderate to severe asthma attack. Pulmon Pharmacol Therapeut 2005; 18: 416-21. http://dx. doi. org/10. 1016/j. pupt. 2005. 03. 003.
38. Aggarwal P, Sharad S, Handa R, Dwiwedi SN, Irshad M. Comparison of nebulised magnesium sulphate and salbutamol combined with salbutamol alone in the treatment of acute bronchial asthma: a randomised study. Emerg Med J 2006; 23: 358-62. http://dx. doi. org/10. 1136/emj. 2005. 026203.
39. Mahajan P, Haritos D, Rosenberg N, Thomas R. Comparison of nebulized magnesium sulfate plus albuterol to nebulized albuterol plus saline in children with acute exacerbations of mild to moderate asthma. J Emerg Med 2004; 27: 21-5. http://dx. doi. org/10. 1016/j. jemermed. 2004. 02. 006.
40. Meral A, Coker M, Tanac R. Inhalation therapy with magnesium sulfate and salbutamol sulfate in bronchial asthma. Turk J Pediatr 1996; 38: 169-75.
41. Mangat HS, D'Souza GA, Jacob MS. Nebulized magnesium sulphate versus nebulized salbutamol in acute bronchial asthma: a clinical trial. Eur Respir J 1998; 12: 341-4. http://dx. doi. org/10. 1183/09031936. 98. 12020341.
42. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomised controlled trials. N Engl J Med 1997; 337: 536-42.
43. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program Expert Panel Report #3: Guidelines for the Diagnosis and Management of Asthma. US Department of Health and Human Services National Institutes of Health National Heart, Lung, and Blood Institute; 2007. URL: www. nhlbi. nih. gov/guidelines/asthma/asthgdln. pdf (accessed 20 January 2014).
44. Jones LA, Goodacre S. Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments. Emerg Med J 2009; 26: 783-5. http://dx. doi. org/10. 1136/emj. 2008. 065938.
45. Hewitt CE, Torgerson DJ. Is restricted randomisation necessary? BMJ 2006; 322: 1506-8. http://dx. doi. org/10. 1136/bmj. 332. 7556. 1506.
46. Wilson RC, Jones PW. Comparison of the visual analogue scale and Borg scale for measurement of dyspnoea during exercise. Clin Sci 1989; 76: 277-82.
47. Kendrick KR, Baxi SC, Smith RM. Usefulness of the modified 0-10 Borg scale in assessing the degree of dyspnea in patients with COPD and asthma. J Emerg Nurs 2000; 26: 216-22.
48. Karras DJ, Sammon ME, Terregino CA, Lopez BL, Griswold SK, Arnold GK. Clinically meaningful changes in quantitative measures of asthma severity. Acad Emerg Med 2000; 7: 327-34. http://dx. doi. org/10. 1111/j. 1553-2712. 2000. tb02231. x.
49. Gupta D, Aggarwal AN, Sublamaxi MV, Jindal SK. Assessing severity of asthma: spirometric correlates with visual analogue scale (VAS). Indian J Chest Dis Allied Sci 2000; 42: 95-100.
50. Simes RJ. An improved Bonferroni procedure for multiple tests of significance. Biometrika 1986; 73: 751-4. http://dx. doi. org/10. 2307/2336545.
51. National Institute for Health and Clinical Excellence. Guide to the Methods of Technology Appraisal. London: National Institute for Health and Clinical Excellence: June; 2008.
52. Payment by Results Team. Reference Costs 2012-12. London: Department of Health; 2012.
53. Curtis L. Unit Costs of Health and Social Care 2011. Canterbury: Personal Social Services Research Unit; 2011.
54. Turner J, O'Cathain A, Knowles E, Nicholl J, Tosh J, Sampson F, et al. Evaluation of NHS 111 Pilot Sites: Final Report. Sheffield: University of Sheffield; 2012. URL: www. sheffield. ac. uk/scharr/sections/hsr/mcru/111 (accessed 6 December 2012).
55. Office for National Statistics. Statistical Bulletin: 2012 Annual Survey of Hours and Earnings. URL: www. ons. gov. uk/ons/dcp171778_286243. pdf (accessed 16 January 2014).
56. Dolan P. Modelling valuations for EurolQoL health states. Med Care 1997; 35: 1095-108 http://dx. doi. org/10. 1097/00005650-199711000-00002.
57. O'Hagan A, Stevens JW, Montmartin J. Bayesian cost-effectiveness analysis from clinical trial data. Stat Med 2001; 20: 733-53. http://dx. doi. org/10. 1002/sim. 861.
58. Lunn DJ, Thomas A, Best N, Spiegelhalter D. WINBUGS-a Bayesian modelling framework: concepts, structure, and extensibility. Stat Comput 2000; 10: 325-37.
59. Griffiths C, Foster G, Barnes N, Eldridge S, Tate H, Begum S, et al. A specialist nurse intervention to reduce unscheduled care for asthma: the East London controlled trial for high risk asthma (ELECTRA). BMJ 2004; 328: 144-7. http://dx. doi. org/10. 1136/bmj. 37950. 784444. EE.
60. Royston P, Altman DG. Approximating statistical functions by using fractional polynomial regression. J R Stat Soc 1997; 46: 411-42. http://dx. doi. org/10. 1111/1467-9884. 00093.
61. The Medicines for Human Use (Clinical Trials) Regulations 2004. URL: www. legislation. gov. uk/uksi/2004/1031/contents/made (accessed 20 January 2014).
62. Coats TJ, Goodacre S. Consent in emergency and resuscitation research. Eur J Emerg Med 2009; 16: 242-3. http://dx. doi. org/10. 1097/MEJ. 0b013e32830fe96a.
63. Coats TJ, Ng G, Shakur H. Consent in emergency research. Emerg Med J 2006; 23: 489-90. http://dx. doi. org/10. 1136/emj. 2005. 031005.
64. Medical Research Council. Guidelines for Good Clinical Practice in Clinical Trials (1998). URL: www. mrc. ac. uk/Utilities/Documentrecord/index. htm?d=MRC002416 (accessed 20 January 2014).
65. Goodacre S, Coats T, Clancy M. Good clinical practice in clinical trials: Core knowledge for emergency physicians. Emerg Med J 2008; 25: 789. http://dx. doi. org/10. 1136/emj. 2008. 063230.
66. Eudralex (European Commission). EU Guidelines for Good Manufacturing Practices for Medicinal Products for Human and Veterinary Use. Volume 4 (Annex 13). URL: http://ec. europa. eu/health/files/eudralex/vol-4/2009_06_annex13. pdf (accessed 20 January 2014).
67. Sheffield Teaching Hospitals. Standard Operating Procedure for Recording, Managing and Recording Adverse Events for STH studies (SOP A123): Version 2. 5. Sheffield; STH: 2009.
68. Kind P, Hardman G, Macran S. UK Population Norms for EQ5D. Centre for Health Economics, University of York; 1999. URL: www. york. ac. uk/inst/che/pdf/DP172. pdf (16 January 2014).
69. Goodacre SW, Bradburn M, Cross E, Collinson PO, Gray A, Hall AS on behalf of the RATPAC research team. The RATPAC Trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers): A randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011; 97: 190-6. http://dx. doi. org/10. 1136/hrt. 2010. 203166.
70. Goodacre S, Nicholl J, Dixon S, Cross E, Angelini K, Arnold J, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004; 328: 254-7. http://dx. doi. org/10. 1136/bmj. 37956. 664236. EE.